ArticleBMC cancer2026
Real-world efficacy and prognostic factor analysis of tislelizumab versus sintilimab in advanced non-small cell lung cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTislelizumab and Sintilimab are commonly used immunotherapy drugs in clinical practice. Only a portion of advanced NSCLC patients achieve sustained remission and long-term survival through ICI immunotherapy, while others experience disease progression post-treatment. Selecting appropriate clinical therapies and predicting treatment efficacy remain significant challenges in clinical practice. By examining the clinical efficacy and safety of tislelizumab and sintilimab combined with chemotherapy in advanced NSCLC patients within real-world settings, and analyzing prognostic factors, this study aims to provide reference for clinical treatment decisions and prognosis assessment. MATERIALS AND
methodsA retrospective analysis of clinical data from 212 patients with advanced NSCLC treated with the combination of tislelizumab or sintilimab plus chemotherapy in The First Affiliated Hospital of Dali University between March 1, 2022, and December 31, 2024. Patients were divided into the tislelizumab group (n = 124) and the sintilimab group (n = 88) based on the administered drug. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were evaluated in both groups. Kaplan-Meier methods were used to plot PFS and OS survival curves. Univariate analysis was performed using the Log-rank test, and Cox regression models were employed to identify independent prognostic factors for PFS and OS.
resultsThe median progression-free survival (mPFS) in the tislelizumab group and the sintilimab group was 14.0 months (95% CI: 11.79-16.21) and 7.0 months (95% CI: 4.31-9.69), respectively (P = 0.005). The difference in mPFS between the two groups was statistically significant. The median overall survival (mOS) was 27.0 months (95% CI: 20.03-33.97) and 24.0 months (95% CI: 13.85-34.15) (P = 0.113), with no statistically significant difference in mOS between groups. ORR was 39.52% versus 18.18% (P < 0.001), showing a statistically significant difference; DCR was 66.13% versus 70.54% (P = 0.506), with no statistically significant difference. After adjustment for confounders, multivariable Cox regression revealed no significant differences between the two agents for PFS (HR = 1.128, 95% CI 0.596-2.133, P = 0.712) or OS (HR = 0.664, 95% CI 0.378-1.165, P = 0.153). ADR occurrence showed a borderline association with improved OS (HR = 0.569, P = 0.093), but was not statistically significant. ALI, PNI, anti-angiogenic combination, and treatment line were not independent prognostic factors (all P > 0.05).
conclusionIn real-world clinical settings, tislelizumab combined with chemotherapy may bring potential improvements in objective response rate and progression-free survival in the short term for patients with advanced NSCLC. Nevertheless, sintilimab and tislelizumab exert comparable long-term survival benefits when used in combination with chemotherapy. After adjusting for confounding factors via multivariable regression analysis, no significant survival differences were confirmed between the two treatment regimens. Further prospective clinical studies with longer follow-up are required to verify the above conclusions.
Indexed as
Identifiers
42888403What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.